Clinical Trials Logo

HPV Vaccine clinical trials

View clinical trials related to HPV Vaccine.

Filter by:

NCT ID: NCT06405048 Not yet recruiting - HPV Vaccine Clinical Trials

Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment

Start date: April 28, 2024
Phase: N/A
Study type: Interventional

The primary objective of this survey experiment study is to measure the impact of a mock-up Chinese fact-checking extension on the ability to dispel HPV and HPV vaccine-related misinformation among parents of middle school girls in China.

NCT ID: NCT06227689 Recruiting - HPV Vaccine Clinical Trials

Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are: 1. How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge of HPV vaccines, their willingness to vaccinate their daughters, and vaccination status of female students. 2. How is the vaccine chatbots accepted by all stakeholders, and what are the facilitators of and barriers to implementing vaccine chatbot promotion campaign. The intervention group will go through the intervention measure while the control group will not: 1. The intervention group will be invited to use the HPV vaccine chatbot online through WeChat , the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention. 2. The control group will not use the chatbot during the intervention duration. Researchers will compare participants' HPV vaccine awareness, and vaccination intention and status after intervention between intervention group and control group to evaluate if the vaccine chatbot improves HPV vaccine awareness and vaccination.

NCT ID: NCT06137352 Not yet recruiting - HPV Infection Clinical Trials

Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity

Start date: December 15, 2023
Phase:
Study type: Observational

This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women aged 13-14 years. A total of 3,000 subjects who have completed 2 doses of the domestic bivalent HPV vaccine and 3 doses of the imported HPV vaccine will be recruited from Fujian Maternal and Child Health Hospital as the initiator of the study, and will be recruited from a number of healthcare institutions nationwide. Of these, 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Wozehui), 1,000 subjects were vaccinated with the domestic bivalent HPV vaccine (Cecolin), and 1,000 subjects were vaccinated with the imported HPV vaccine. Each subject was enrolled within 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and a total of two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine. In response to the WHO Cervical Cancer Elimination Strategy, domestic bivalent HPV vaccine has been offered free of charge to adolescent females aged 13-14 years, but there is still a lack of evidence comparing the antibody titer levels of domestic HPV vaccine and imported HPV vaccine in younger females. Therefore, we conducted the present immunogenicity study to explore the immunogenicity and immune persistence after vaccination with domestic bivalent HPV vaccine versus imported HPV vaccine in this age group of females.

NCT ID: NCT06105346 Not yet recruiting - Long COVID Clinical Trials

Prevalence of ENT Diseseas

PrENT
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of long-COVID symptoms and further, to evaluate different factors that influence on the one hand the prevalence (urban-bred, non-urban-bred) and on the other hand symptoms (ENT-surgeries in medical history). Further, we want to evaluate if there is a correlation between subjective symptoms and apparated-based diagnostic investigations. Therefore, questionnaires and data of medical examinations, aquired routinely at the military induction board, will be analysed.

NCT ID: NCT05291871 Active, not recruiting - HPV Infection Clinical Trials

Immunogenicity of Fractional Dose of the HPV Vaccines

Start date: June 15, 2022
Phase: Phase 4
Study type: Interventional

This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months

NCT ID: NCT05105711 Completed - HPV Vaccine Clinical Trials

Mobile Coaching to Improve HPV Vaccine Delivery

Start date: June 21, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the feasibility of using Checkup Coach, a mobile coaching intervention, to improve the way that primary care providers recommend HPV vaccination to adolescent patients and their parents. To conduct this feasibility study, the investigators will deliver the Checkup Coach intervention to 20 Kaiser Permanente Washington primary care providers who routinely recommend HPV vaccine to adolescent patients. The investigators will use a single-arm, pre-post design. Participating primary care providers will attend a 1-hour virtual communication workshop and then use a mobile phone app to receive additional coaching for 12 weeks. Providers will complete surveys at three time points: before the communication workshop, immediately after the workshop, and at 12-week follow-up. Surveys will assess changes in providers' self-reported HPV vaccine recommendation practices and beliefs about HPV vaccine and also acceptability of the intervention. The investigators hypothesizes that providers' HPV vaccine communication will improve between baseline and 12-week follow-up.

NCT ID: NCT04982614 Active, not recruiting - Hiv Clinical Trials

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, as well as measuring the completion of the vaccination series among those living with HIV and those who are not infected with HIV.

NCT ID: NCT04974619 Completed - HPV Clinical Trials

Adaptation Of An HPV Education Resource To Promote HPV Vaccination

Start date: July 23, 2021
Phase:
Study type: Observational

The purpose of the study is to assess Human Papillomavirus (HPV) and HPV vaccination knowledge, awareness, attitudes, health beliefs, and behaviors as well as educational preferences for learning more about HPV and HPV vaccination and to receive feedback on and adapt HPV educational materials for Young Latino Men who have Sex with Men (YLMSM).

NCT ID: NCT04711265 Completed - HIV-1-infection Clinical Trials

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

Start date: September 2015
Phase:
Study type: Observational

Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls and boys in Kenya'.

NCT ID: NCT04235257 Active, not recruiting - HPV Infection Clinical Trials

Intradermal, Fractional Dose of HPV Vaccines:

Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.